Keros Therapeutics (KROS) director submits initial Form 3 ownership

Rhea-AI Filing Summary

Keros Therapeutics, Inc. director Charles W. Newton has filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a reporting insider of the company and records his starting position for future ownership and transaction disclosures.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Newton Charles W.

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/09/2026

3. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Esther Cho, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 3 filed by Keros Therapeutics (KROS) director Charles W. Newton show?

The Form 3 for Keros Therapeutics director Charles W. Newton records his initial beneficial ownership status. It establishes him as a reporting insider and provides a baseline for any future changes in his holdings that must be reported to investors.

Does the Keros Therapeutics (KROS) Form 3 for Charles W. Newton report any share transactions?

The Form 3 for Charles W. Newton does not report any insider buy or sell transactions. Instead, it functions as an initial ownership statement, setting the starting point from which later Form 4 or Form 5 transaction reports will be compared.

What is the purpose of Charles W. Newton’s Form 3 at Keros Therapeutics (KROS)?

Charles W. Newton’s Form 3 serves to disclose his status as a beneficial owner and director of Keros Therapeutics. It provides transparency for investors by ensuring any future changes in his ownership will be tracked through subsequent SEC filings.

How does the Form 3 for Keros Therapeutics (KROS) affect investors?

The Form 3 itself does not change Keros Therapeutics’ financial position but improves transparency. It identifies Charles W. Newton as an insider whose future trades in company securities will be publicly reported, helping investors monitor insider activity over time.

Is the Keros Therapeutics (KROS) Form 3 filing for Charles W. Newton routine?

Yes, the Form 3 for Charles W. Newton is a routine regulatory filing. It is typically required when someone becomes a director, officer, or large shareholder, and it establishes their initial ownership position without signaling any immediate trading activity.